Abbott

XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for Treatment of Coronary Artery Disease

Abbott Park, Illinois, July 2, 2008 -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) approved the XIENCE™ V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE V is the only drug eluting stent to have demonstrated superiority over Boston Scientific's TAXUS® paclitaxel-eluting coronary stent system in two randomized head-to-head clinical trials. XIENCE V will be launched in the United States immediately.    » read more »

March 18, 2008 -- Jefferson City, Mo. — Missouri Attorney General Jay Nixon was joined by 17 other states and the District of Columbia today in filing a lawsuit against pharmaceutical companies Abbott Laboratories and Fournier. The lawsuit alleges that the companies conspired to violate antitrust laws in delaying the availability of a cheaper, generic version of the cholesterol drug TriCor. TriCor accounted for over one billion dollars in sales for Abbott one year ago.    » read more »

BALTIMORE, MD (March 18, 2008) - Maryland Attorney General Douglas F. Gansler today filed suit against Abbott Laboratories and French drug company Fournier Industrie et Sante alleging that the firms violated state and federal antitrust laws by delaying the availability of cheaper, generic versions of TriCor, a cholesterol drug which last year accounted for over one billion dollars of Abbott’s sales.    » read more »

Abbott and French drug company face allegations they blocked generic versions of a cholesterol drug

March 18, 2008 -- TALLAHASSEE, FL – Florida Attorney General Bill McCollum today announced that Florida and 18 states have filed an antitrust lawsuit against Abbott Laboratories and French drug company Fournier Industrie et Sante and Laboratories Fournier, S.A., charging the companies with blocking a cheaper, generic version of prescription drug TriCor.    » read more »

Abbott Park, Illinois, October 10, 2007 – Abbott has been named to Hispanic Business magazine's list of the nation's best companies for Hispanics. Abbott was recognized as one of the magazine’s "Diversity Elite 60" companies for its commitment to Hispanic hiring, promotion, marketing, philanthropy and supplier diversity.    » read more »